JP2005522422A - 医薬組成物 - Google Patents
医薬組成物 Download PDFInfo
- Publication number
- JP2005522422A JP2005522422A JP2003563518A JP2003563518A JP2005522422A JP 2005522422 A JP2005522422 A JP 2005522422A JP 2003563518 A JP2003563518 A JP 2003563518A JP 2003563518 A JP2003563518 A JP 2003563518A JP 2005522422 A JP2005522422 A JP 2005522422A
- Authority
- JP
- Japan
- Prior art keywords
- propofol
- cyclodextrin
- pharmaceutical composition
- vial
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 30
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 claims abstract description 73
- 229960004134 propofol Drugs 0.000 claims abstract description 72
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 55
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims abstract description 28
- 239000002552 dosage form Substances 0.000 claims abstract description 6
- 238000004519 manufacturing process Methods 0.000 claims abstract description 4
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims description 36
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 238000004108 freeze drying Methods 0.000 claims description 5
- 238000007710 freezing Methods 0.000 claims description 4
- 230000008014 freezing Effects 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 239000000203 mixture Substances 0.000 abstract description 27
- 239000000243 solution Substances 0.000 description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 238000003756 stirring Methods 0.000 description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 239000007787 solid Substances 0.000 description 7
- 239000001116 FEMA 4028 Substances 0.000 description 6
- 229960004853 betadex Drugs 0.000 description 6
- 238000001990 intravenous administration Methods 0.000 description 5
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 5
- 229960000991 ketoprofen Drugs 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 239000008215 water for injection Substances 0.000 description 5
- 206010002091 Anaesthesia Diseases 0.000 description 4
- 241000792859 Enema Species 0.000 description 4
- 230000037005 anaesthesia Effects 0.000 description 4
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 4
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 4
- -1 cyclic oligosaccharides Chemical class 0.000 description 4
- 229940097362 cyclodextrins Drugs 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000007920 enema Substances 0.000 description 4
- 229940095399 enema Drugs 0.000 description 4
- 239000002960 lipid emulsion Substances 0.000 description 4
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000006184 cosolvent Substances 0.000 description 3
- 238000000113 differential scanning calorimetry Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 238000004566 IR spectroscopy Methods 0.000 description 2
- 206010022086 Injection site pain Diseases 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 230000003444 anaesthetic effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 230000009918 complex formation Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- 238000002798 spectrophotometry method Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- YZOUYRAONFXZSI-SBHWVFSVSA-N (1S,3R,5R,6R,8R,10R,11R,13R,15R,16R,18R,20R,21R,23R,25R,26R,28R,30R,31S,33R,35R,36R,37S,38R,39S,40R,41S,42R,43S,44R,45S,46R,47S,48R,49S)-5,10,15,20,25,30,35-heptakis(hydroxymethyl)-37,39,40,41,42,43,44,45,46,47,48,49-dodecamethoxy-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontane-36,38-diol Chemical compound O([C@@H]([C@H]([C@@H]1OC)OC)O[C@H]2[C@@H](O)[C@@H]([C@@H](O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3O)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O3)O[C@@H]2CO)OC)[C@H](CO)[C@H]1O[C@@H]1[C@@H](OC)[C@H](OC)[C@H]3[C@@H](CO)O1 YZOUYRAONFXZSI-SBHWVFSVSA-N 0.000 description 1
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
- 241001535291 Analges Species 0.000 description 1
- LVDKZNITIUWNER-UHFFFAOYSA-N Bronopol Chemical compound OCC(Br)(CO)[N+]([O-])=O LVDKZNITIUWNER-UHFFFAOYSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 235000014755 Eruca sativa Nutrition 0.000 description 1
- 244000024675 Eruca sativa Species 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 239000007798 antifreeze agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 238000012865 aseptic processing Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229960003168 bronopol Drugs 0.000 description 1
- 239000008364 bulk solution Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000004686 fractography Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 150000002634 lipophilic molecules Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000012931 lyophilized formulation Substances 0.000 description 1
- FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- 239000004323 potassium nitrate Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000004648 relaxation of smooth muscle Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Anesthesiology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ZA200200929 | 2002-02-01 | ||
| US40163302P | 2002-08-06 | 2002-08-06 | |
| PCT/IB2003/000266 WO2003063824A2 (en) | 2002-02-01 | 2003-01-29 | Pharmaceutical composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005522422A true JP2005522422A (ja) | 2005-07-28 |
| JP2005522422A5 JP2005522422A5 (enExample) | 2006-03-16 |
Family
ID=27669352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003563518A Pending JP2005522422A (ja) | 2002-02-01 | 2003-01-29 | 医薬組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20050239746A1 (enExample) |
| EP (1) | EP1469886B8 (enExample) |
| JP (1) | JP2005522422A (enExample) |
| CN (1) | CN1625414A (enExample) |
| AT (1) | ATE326985T1 (enExample) |
| AU (1) | AU2003205930B2 (enExample) |
| BR (1) | BR0307518A (enExample) |
| CA (1) | CA2474710A1 (enExample) |
| DE (1) | DE60305438T2 (enExample) |
| MX (1) | MXPA04007328A (enExample) |
| NZ (1) | NZ534598A (enExample) |
| WO (1) | WO2003063824A2 (enExample) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011516441A (ja) * | 2008-04-04 | 2011-05-26 | ノルベルト・レーヴァー | ペルメチル化シクロデキストリンを含む医薬製剤 |
| JP2015145364A (ja) * | 2011-11-29 | 2015-08-13 | ジュロックス プロプライエタリー リミテッド | 薬学的組成物 |
| US9925274B2 (en) | 2012-11-15 | 2018-03-27 | Sapiotec Gmbh | Delphinidin complex as an antiphlogistic or immunosuppressive active ingredient |
| US9949947B2 (en) | 2012-12-11 | 2018-04-24 | Sapiotec Gmbh | Delphinidin for combating melanoma cells |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE364402T1 (de) * | 2004-03-10 | 2007-07-15 | Shimoda Biotech Pty Ltd | Stabile injizierbare diclofenac- zubereitungen |
| US20060198891A1 (en) | 2004-11-29 | 2006-09-07 | Francois Ravenelle | Solid formulations of liquid biologically active agents |
| WO2006112276A1 (ja) | 2005-04-13 | 2006-10-26 | Otsuka Pharmaceutical Factory, Inc. | プロポフォール含有脂肪乳剤 |
| US20090203794A1 (en) * | 2005-08-12 | 2009-08-13 | Gautam Vinod Daftary | Aqueous Anaesthetic Composition Comprising Propofol |
| US8580954B2 (en) | 2006-03-28 | 2013-11-12 | Hospira, Inc. | Formulations of low dose diclofenac and beta-cyclodextrin |
| DK2484350T3 (en) * | 2011-02-04 | 2016-08-01 | Norbert Univ -Prof Dr Med Roewer | A pharmaceutical composition containing a complex of a cyclodextrin with a propofolsalt |
| CN103172658B (zh) * | 2011-12-26 | 2016-01-20 | 宜昌人福药业有限责任公司 | 一种适合药用的前体药物晶型、制备方法及药用组合物 |
| EP2913050A1 (de) * | 2014-02-28 | 2015-09-02 | SapioTec GmbH | Verfahren zur Herstellung eines Flurankomplexes |
| CN104523591B (zh) * | 2014-12-19 | 2019-01-18 | 西安力邦肇新生物科技有限公司 | 无致敏性、无痛丙泊酚脂肪微乳冻干制剂配方和制备方法 |
| CN111529695A (zh) * | 2020-04-30 | 2020-08-14 | 首都医科大学附属北京康复医院（北京工人疗养院） | 一种环糊精可溶性ace2及其制备方法和应用 |
| KR20220057901A (ko) * | 2020-10-30 | 2022-05-09 | 현대자동차주식회사 | 차아염소산수를 이용한 차량용 살균장치 및 그 제어방법 |
| FR3117337B1 (fr) | 2020-12-10 | 2023-04-28 | Centre Hospitalier Univ De Lille | Composition pharmaceutique contenant du propofol, une cyclodextrine ou un dérivé de cyclodextrine et un sel pharmaceuticalement acceptable |
| KR20240148426A (ko) * | 2022-02-18 | 2024-10-11 | 베렌 테라퓨틱스 피.비.씨. | 2-히드록시프로필-베타-사이클로덱스트린으로 고-트리글리세리드혈증을 치료 |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58146504A (ja) * | 1981-12-23 | 1983-09-01 | シエリング・コーポレーシヨン | α―インターフェロン製剤およびその製造方法 |
| WO1996032135A1 (en) * | 1995-04-10 | 1996-10-17 | Farmarc Nederland Bv Of Citco Trust International Management (T.I.M.) B.V. | Pharmaceutical composition |
| WO2000029025A1 (en) * | 1998-11-16 | 2000-05-25 | U.S. Bioscience, Inc. | Stable amorphous amifostine compositions and methods for the preparation and use of same |
| JP2000511510A (ja) * | 1996-02-19 | 2000-09-05 | ニユコメド・イメージング・アクシエセルカペト | 造影剤のまたはそれに関する改良 |
| WO2001024817A2 (en) * | 1999-10-01 | 2001-04-12 | Amgen Inc. | Pharmaceutical compositions of fibrinolytic agent |
| WO2001032172A1 (en) * | 1999-10-29 | 2001-05-10 | Merck & Co., Inc. | Process for formulation of carbapenem antibiotic compositions |
| WO2002074200A1 (en) * | 2001-03-20 | 2002-09-26 | Cydex, Inc. | Formulations containing propofol and a sulfoalkyl ether cyclodextrin |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5774796A (en) * | 1995-06-13 | 1997-01-09 | Dyer, Alison Margaret | Pharmaceutical compositions containing lornoxicam and cyclod extrin |
| IN187686B (enExample) * | 2000-06-21 | 2002-06-08 | Bharat Serums & Vaccines Ltd |
-
2003
- 2003-01-29 DE DE60305438T patent/DE60305438T2/de not_active Expired - Lifetime
- 2003-01-29 MX MXPA04007328A patent/MXPA04007328A/es unknown
- 2003-01-29 CA CA002474710A patent/CA2474710A1/en not_active Abandoned
- 2003-01-29 BR BR0307518-4A patent/BR0307518A/pt not_active IP Right Cessation
- 2003-01-29 EP EP03702813A patent/EP1469886B8/en not_active Expired - Lifetime
- 2003-01-29 JP JP2003563518A patent/JP2005522422A/ja active Pending
- 2003-01-29 NZ NZ534598A patent/NZ534598A/en not_active IP Right Cessation
- 2003-01-29 CN CNA038031442A patent/CN1625414A/zh active Pending
- 2003-01-29 AT AT03702813T patent/ATE326985T1/de not_active IP Right Cessation
- 2003-01-29 AU AU2003205930A patent/AU2003205930B2/en not_active Ceased
- 2003-01-29 US US10/503,067 patent/US20050239746A1/en not_active Abandoned
- 2003-01-29 WO PCT/IB2003/000266 patent/WO2003063824A2/en not_active Ceased
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58146504A (ja) * | 1981-12-23 | 1983-09-01 | シエリング・コーポレーシヨン | α―インターフェロン製剤およびその製造方法 |
| WO1996032135A1 (en) * | 1995-04-10 | 1996-10-17 | Farmarc Nederland Bv Of Citco Trust International Management (T.I.M.) B.V. | Pharmaceutical composition |
| JP2000511510A (ja) * | 1996-02-19 | 2000-09-05 | ニユコメド・イメージング・アクシエセルカペト | 造影剤のまたはそれに関する改良 |
| WO2000029025A1 (en) * | 1998-11-16 | 2000-05-25 | U.S. Bioscience, Inc. | Stable amorphous amifostine compositions and methods for the preparation and use of same |
| WO2001024817A2 (en) * | 1999-10-01 | 2001-04-12 | Amgen Inc. | Pharmaceutical compositions of fibrinolytic agent |
| WO2001032172A1 (en) * | 1999-10-29 | 2001-05-10 | Merck & Co., Inc. | Process for formulation of carbapenem antibiotic compositions |
| WO2002074200A1 (en) * | 2001-03-20 | 2002-09-26 | Cydex, Inc. | Formulations containing propofol and a sulfoalkyl ether cyclodextrin |
| JP2004526730A (ja) * | 2001-03-20 | 2004-09-02 | サイデックス・インコーポレイテッド | プロポフォール及びスルホアルキルエーテルシクロデキストリン含有製剤 |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011516441A (ja) * | 2008-04-04 | 2011-05-26 | ノルベルト・レーヴァー | ペルメチル化シクロデキストリンを含む医薬製剤 |
| US8980882B2 (en) | 2008-04-04 | 2015-03-17 | Norbert Roewer | Pharmaceutical preparation comprising permethylated cyclodextrin |
| JP2015145364A (ja) * | 2011-11-29 | 2015-08-13 | ジュロックス プロプライエタリー リミテッド | 薬学的組成物 |
| US9925274B2 (en) | 2012-11-15 | 2018-03-27 | Sapiotec Gmbh | Delphinidin complex as an antiphlogistic or immunosuppressive active ingredient |
| US9949947B2 (en) | 2012-12-11 | 2018-04-24 | Sapiotec Gmbh | Delphinidin for combating melanoma cells |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1469886A2 (en) | 2004-10-27 |
| ATE326985T1 (de) | 2006-06-15 |
| MXPA04007328A (es) | 2005-07-05 |
| EP1469886B1 (en) | 2006-05-24 |
| NZ534598A (en) | 2004-11-26 |
| DE60305438T2 (de) | 2006-12-21 |
| WO2003063824A3 (en) | 2004-06-17 |
| WO2003063824A2 (en) | 2003-08-07 |
| AU2003205930B2 (en) | 2007-08-16 |
| CN1625414A (zh) | 2005-06-08 |
| US20050239746A1 (en) | 2005-10-27 |
| CA2474710A1 (en) | 2003-08-07 |
| BR0307518A (pt) | 2004-12-28 |
| DE60305438D1 (de) | 2006-06-29 |
| EP1469886B8 (en) | 2008-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005522422A (ja) | 医薬組成物 | |
| JP4764004B2 (ja) | アミオダロンおよびスルホアルキルエーテルシクロデキストリンを含む製剤 | |
| KR100349754B1 (ko) | 제약조성물 | |
| US7678776B2 (en) | Inclusion complexes of butylphthalide with cyclodextrin or its derivatives, a process for their preparation and the use thereof | |
| AU2003205930A1 (en) | Pharmaceutical composition | |
| JP3140409B2 (ja) | 安定なプロスタグランジンｅ１−含有注射剤組成物 | |
| JP2018535943A (ja) | 輸液又は注射として及び輸液濃縮物の静脈内投与のためのレボシメンダンの改善された調製物 | |
| US6077871A (en) | Droloxifene pharmaceutical compositions | |
| JP7526175B2 (ja) | Ｂｃｌ－２阻害剤のシクロデキストリンに基づく製剤 | |
| JP2009504634A (ja) | プロポフォールを含む水性麻酔剤組成物 | |
| JP2003321364A (ja) | シクロデキストリンにより可溶化及び安定化された抗腫瘍剤含有組成物 | |
| AU777684B2 (en) | Formulations for parenteral use of estramustine phosphate and sulfoalkyl ether cyclodextrins | |
| EP2035040B1 (en) | Pharmaceutical composition for administration by injection | |
| KR20040091004A (ko) | 약제학적 조성물 | |
| JP4475405B2 (ja) | 医薬組成物 | |
| CN101137364B (zh) | 包含埃坡霉素的组合物及其制备方法 | |
| JP2007519702A (ja) | ニューロキニン受容体拮抗薬及びシクロデキストリンからなる医薬組成物、ならびに注射部位の耐容性を改善するための方法 | |
| ZA200406021B (en) | Pharmaceutical composition | |
| AU777763B2 (en) | Formulations for parenteral use of estramustine phosphate with improved pharmacological properties | |
| JP2003089632A (ja) | 注射用水性製剤 | |
| JPH02172913A (ja) | ポリプレニル系化合物含有注射剤 | |
| MXPA98009888A (en) | Pharmaceutical compositions of droloxif |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20060126 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060126 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090828 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091130 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091207 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091228 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100108 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100420 |